HilleVax, Inc. (HLVX)

Market Cap	597.40M
Revenue (ttm)	n/a
Net Income (ttm)	-123.57M
Shares Out	49.70M
EPS (ttm)	-3.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	44,891
Open	12.22
Previous Close	12.58
Day's Range	11.79 - 12.40
52-Week Range	9.94 - 20.22
Beta	n/a
Analysts	Strong Buy
Price Target	28.50 (+137.11%)
Earnings Date	May 10, 2024

About HLVX

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 29, 2022
• Employees: 90
• Stock Exchange: NASDAQ
• Ticker Symbol: HLVX

Analyst Forecast

According to 4 analysts, the average rating for HLVX stock is "Strong Buy." The 12-month stock price forecast is $28.5, which is an increase of 137.11% from the latest price.

Price Target

$28.5

(137.11% upside)

Analyst Consensus: Strong Buy